NCT00038675 · OUTCOME

Overall Survival

Therapy of HES, PV, Atypical Chronic Myelocytic Leukemia (CML) or Chronic Myelomonocytic Leukemia (CMML), and Mastocytosis With Imatinib Mesylate · Source last updated 2022-01-04

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure: MEDIAN
Unit: Months
Interval / dispersion: Full Range
Time frame: From the start of therapy to death or disease progression, assessed up to 12 years and 5 months

What was measured

Overall survival defined as time from registration to disease progression or death from any cause.

Groups in this outcome

Imatinib Mesylate

Imatinib mesylate 400 mg orally daily, HES participants start with 100 mg orally daily.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

Group	Source count
Imatinib Mesylate	125

Reported measurements

Source class 1

Values in Months · Interval/dispersion: Full Range
Group	Value	Spread	Lower	Upper	Comment
Imatinib Mesylate	73.2	Not reported	0.3	149	Not reported

Complete source fields

classes

categories
measurements
group Id
OG000
lower Limit
0.3
upper Limit
149
value
73.2

denoms

counts
group Id
OG000
value
125
units
Participants

description

Overall survival defined as time from registration to disease progression or death from any cause.

dispersion Type

Full Range

groups

description
Imatinib mesylate 400 mg orally daily, HES participants start with 100 mg orally daily.
id
OG000
title
Imatinib Mesylate

param Type

MEDIAN

reporting Status

POSTED

time Frame

From the start of therapy to death or disease progression, assessed up to 12 years and 5 months

title

Overall Survival

type

SECONDARY

unit Of Measure

Months

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice